/CINC

CINC Stock - CinCor Pharma, Inc.

Q: What is the analyst price target for CINC?

Analyst price target information is not currently available for CINC.

Q: What is CINC's market cap?

Market capitalization information is not currently available for CINC.

Healthcare|Biotechnology|NASDAQ

$29.06+0.00%

+$0.00 (+0.00%) • Feb 23

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+36.5%upside

Target: $39.67

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CINC

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.00

52W High$43.15

52W Low$10.53

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2021	FY2020	FY2019
Revenue	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A
Operating Income	$-42,510,406	$-21,125,445	$-5,136,816
Net Income	$-50,347,433	$-22,261,817	$-4,933,404
Net Margin	N/A	N/A	N/A
EPS	$-1.42	$-0.95	$-0.21

Company Overview

CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

50%

Hold / Neutral

50%

Sell / Underperform

Analyst Consensus🟡 Mixed

1 Bullish1 Neutral/Bearish

Price Targets

$46

Average Target

↑ 58.3% Upside

Now

$22

Low

$46

Average

$73

High

Based on 4 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
December 7th 2022	Barclays	Initiation	Overweight	$22
November 29th 2022	Oppenheimer	Downgrade	Perform	-
November 29th 2022	Morgan Stanley	Downgrade	Equal Weight	$22← $60
October 28th 2022	Goldman	Initiation	Buy	$67
August 22nd 2022	Piper Sandler	Initiation	Overweight	$73

Earnings History & Surprises

CINC

Beat Rate

25%

Last 4 quarters

Avg Surprise

-225.7%

EPS vs Estimate

Beats / Misses

1/2

1 met exactly

Latest EPS

$-0.51

Q4 2022

EPS Surprise History

Q4 20

No data

Q1 21

No data

Q2 21

No data

Q3 21

No data

Q1 22

-907.1%

$-15.71vs$-1.56

Q2 22

0.0%

$-0.50vs$-0.50

Q3 22

-12.0%

$-0.56vs$-0.50

Q4 22

+16.4%

$-0.51vs$-0.61

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2023	Mar 28, 2023	$-0.55	—	—	—
Q4 2022	Nov 3, 2022	$-0.61	$-0.51	+16.4%	✓ BEAT
Q3 2022	Aug 8, 2022	$-0.50	$-0.56	-12.0%	✗ MISS
Q2 2022	May 10, 2022	$-0.50	$-0.50	0.0%	= MET
Q1 2022	Mar 22, 2022	$-1.56	$-15.71	-907.1%	✗ MISS
Q3 2021	Sep 30, 2021	—	$-0.25	—	—
Q2 2021	Jun 30, 2021	—	$-0.19	—	—
Q1 2021	Mar 31, 2021	—	$-0.16	—	—
Q4 2020	Dec 31, 2020	—	$-0.16	—	—